ADVA
27.10.2020 09:02:14 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has joined the O-RAN ALLIANCE, a global ecosystem of mobile network operators and technology suppliers driving intelligent, virtualized and fully interoperable mobile networks. ADVA’s experience and technology leadership will help the O-RAN ALLIANCE community create innovative open transport solutions. With its 5G X-Haul toolbox comprising optical, packet, edge compute, and timing distribution and assurance technology, ADVA will assist O-RAN ALLIANCE to develop open standards. These will enable the deployment and operation of disaggregated, vendor-neutral RAN infrastructure for a new generation of mobile services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005076/en/
“Our long-standing commitment to openness aligns perfectly with the O-RAN ALLIANCE’s goals. By joining the community and adding our end-to-end solution portfolio to the mix, we’re helping develop specifications for LTE, 5G and beyond and accelerating the deployment of next-generation mobile network architectures,” said Anthony Magee, senior director, global business development, mobile, ADVA. “One of the key elements we’re bringing to the table is our innovative approach to disaggregation. By working closely with our O-RAN partners, we’re helping to extend this into radio access networks, breaking down barriers and creating a disaggregated, centralized model with virtualized RAN.“
ADVA’s portfolio of open X-Haul technology will help to enhance the O-RAN ALLIANCE ecosystem. Products such as the ADVA FSP 150-XG118Pro provide 10Gbit/s capacity at the radio base station and feature a compute shelf for hosting O-RAN capabilities. ADVA’s self-tuning G.metro solution also makes it simple to deploy architectures for low-latency 5G fronthaul. Virtualized RAN technology will be another key element of tomorrow’s mobile infrastructure. ADVA’s Ensemble NFV software enables operators to utilize VNFs on open servers that are centrally coordinated and automatically activated. The O-RAN ALLIANCE is also dedicated to embedding intelligence throughout the RAN infrastructure. To support the power of 5G to transform operations, ADVA FSP 150 devices complement small cell technologies with powerful, intelligent edge capabilities. And finally, ADVA’s timing distribution solutions deliver the accuracy needed for advanced radio configurations or precise location services.
“Synchronization is fundamental to 5G access network architecture. For many 5G applications, sub-100nsec timing accuracy and ultra-reliability are crucial requirements. That’s why the experience and innovation of our Oscilloquartz team of network timing specialists is one of the most significant areas of expertise we’re bringing to the O-RAN ALLIANCE,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “With our small-form-factor OSA 5401 PTP grandmaster device and our OSA 5405 integrated PTP grandmaster solutions, we’re supporting sub-100nsec timing for mobile network fronthaul. These technologies enable MNOs to smoothly transition to next-generation synchronization and provide the scale required to meet the needs of 5G and beyond.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005076/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom